187 related articles for article (PubMed ID: 34230114)
1. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
Vonderheide RH; Kraynyak KA; Shields AF; McRee AJ; Johnson JM; Sun W; Chintakuntlawar AV; Pawlicki J; Sylvester AJ; McMullan T; Samuels R; Kim JJ; Weiner D; Boyer JD; Morrow MP; Humeau L; Skolnik JM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230114
[TBL] [Abstract][Full Text] [Related]
2. CD8
Shore ND; Morrow MP; McMullan T; Kraynyak KA; Sylvester A; Bhatt K; Cheung J; Boyer JD; Liu L; Sacchetta B; Rosencranz S; Heath EI; Nordquist L; Cheng HH; Tagawa ST; Appleman LJ; Tutrone R; Garcia JA; Whang YE; Kelly WK; Weiner DB; Bagarazzi ML; Skolnik JM
Mol Ther; 2020 May; 28(5):1238-1250. PubMed ID: 32208168
[TBL] [Abstract][Full Text] [Related]
3. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378
[TBL] [Abstract][Full Text] [Related]
4. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
7. A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Teixeira L; Medioni J; Garibal J; Adotevi O; Doucet L; Durey MD; Ghrieb Z; Kiladjian JJ; Brizard M; Laheurte C; Wehbe M; Pliquet E; Escande M; Defrance R; Culine S; Oudard S; Wain-Hobson S; Doppler V; Huet T; Langlade-Demoyen P
Clin Cancer Res; 2020 Feb; 26(3):588-597. PubMed ID: 31558479
[TBL] [Abstract][Full Text] [Related]
8. Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Cheung J; Dickerson K; Schulten V; Knoblock D; Gillespie E; Bauml JM; Yan J; Diehl M; Boyer J; Dallas M; Kim JJ; Weiner DB; Skolnik JM
Vaccines (Basel); 2020 Jan; 8(1):. PubMed ID: 32013270
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.
Aurisicchio L; Fridman A; Mauro D; Sheloditna R; Chiappori A; Bagchi A; Ciliberto G
J Transl Med; 2020 Jan; 18(1):39. PubMed ID: 32000810
[TBL] [Abstract][Full Text] [Related]
11. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors.
Frolkis M; Fischer MB; Wang Z; Lebkowski JS; Chiu CP; Majumdar AS
Cancer Gene Ther; 2003 Mar; 10(3):239-49. PubMed ID: 12637945
[TBL] [Abstract][Full Text] [Related]
15. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
[TBL] [Abstract][Full Text] [Related]
16. Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.
Thalmensi J; Pliquet E; Liard C; Escande M; Bestetti T; Julithe M; Kostrzak A; Pailhes-Jimenez AS; Bourges E; Loustau M; Caumartin J; Lachgar A; Huet T; Wain-Hobson S; Langlade-Demoyen P
Oncoimmunology; 2016 Mar; 5(3):e1083670. PubMed ID: 27141336
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors.
Choi W; Lee Y; Choi BK; Park BM; Kim YH; Yun T; Lee WJ; Yoo H; Baek JY; Woo SM; Lim MC; Kwon BS
Cytotherapy; 2023 Nov; 25(11):1236-1241. PubMed ID: 37632518
[TBL] [Abstract][Full Text] [Related]
19. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
